- support
- info@evidentic.com
- +49 (0) 30 959 99 8831
Aliquots are pre-aliquoted, commercially available drugs from the EU. Our aliquots thus contain therapeutic molecules manufactured by the original drug license holder and repackaged by Evidentic.
ProductBatch | Antigen | Molecular Class | Drug Brand | Product Concentration | CoA | Quantity per vial | Storage Temperature | Expiry Date | Price from | |
---|---|---|---|---|---|---|---|---|---|---|
EGFR |
Monoclonal Antibody |
Vectibix® |
20 mg/mL |
– |
2 mg |
-80 °C |
02/2025 |
230,00 € |
||
PD-1 |
Monoclonal Antibody |
Keytruda® |
25 mg/mL |
– |
2 mg |
-80°C |
07/2018 |
451,80 € |
||
PD-1 |
Monoclonal Antibody |
Keytruda® |
25 mg/mL |
– |
2 mg |
-80°C |
12/2018 |
451,80 € |
||
PD-1 |
Monoclonal Antibody |
Keytruda® |
25 mg/mL |
– |
2 mg |
-80°C |
03/2019 |
451,80 € |
||
PD-1 |
Monoclonal Antibody |
Keytruda® |
25 mg/mL |
– |
2 mg |
-80°C |
07/2019 |
451,80 € |
||
PD-1 |
Monoclonal Antibody |
Keytruda® |
25 mg/mL |
yes |
2 mg |
-80°C |
04/2022 |
564,30 € |
||
PD-1 |
Monoclonal Antibody |
Keytruda® |
25 mg/mL |
– |
2 mg |
-80°C |
11/2022 |
451,80 € |
||
PD-1 |
Monoclonal Antibody |
Keytruda® |
25 mg/mL |
– |
2 mg |
-80°C |
04/2024 |
502,00 € |
||
HER2 |
Monoclonal Antibody |
Perjeta® |
30 mg/mL |
yes |
6 mg |
-80°C |
11/2020 |
419,40 € |
||
CD79b |
Antibody-drug conjugate (ADC) |
Polivy® |
20 mg/mL |
– |
1 mg |
-80 °C |
06/2024 |
536,00 € |
||
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
03/2018 |
182,70 € |
||
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
06/2018 |
182,70 € |
||
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
08/2018 |
182,70 € |
||
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
01/2019 |
182,70 € |
||
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
12/2019 |
182,70 € |
||
VEGFR2 |
Monoclonal Antibody |
Cyramza® |
10 mg/mL |
– |
2 mg |
-80°C |
06/2020 |
182,70 € |
||
VEGF-A |
Monoclonal Antibody |
Lucentis® |
10 mg/mL |
– |
0.2 mg |
tba |
tba |
680,00 € |
||
VEGF-A |
Biosimilar , Monoclonal Antibody |
Ranivisio® |
10 mg/mL |
– |
0.2 mg |
tba |
tba |
680,00 € |
||
VEGF |
Biosimilar , Monoclonal Antibody |
Ximluci® |
10 mg/mL |
– |
0,21 mg |
tba |
tba |
680,00 € |
||
VEGF |
Monoclonal Antibody |
Byooviz® |
10 mg/mL |
– |
0,21 mg |
tba |
tba |
621,00 € |
||
C5 complement protein |
Monoclonal Antibody |
Ultomiris® |
10 mg/mL |
– |
10 mg |
tba |
tba |
2.193,00 € |
||
IL-23 |
Monoclonal Antibody |
Skyrizi® |
150 mg/mL |
yes |
6 mg |
-80°C |
04/2023 |
931,50 € |
||
IL-23 |
Monoclonal Antibody |
Skyrizi® |
150 mg/mL |
yes |
6 mg |
-80°C |
03/2024 |
931,50 € |
||
IL-23 |
Monoclonal Antibody |
Skyrizi® |
150 mg/mL |
yes |
6 mg |
-80°C |
05/2024 |
1.035,00 € |
||
CD20 |
Biosimilar , Monoclonal Antibody |
Ruxience® |
10 mg/mL |
– |
2 mg |
tba |
tba |
196,00 € |
||
CD20 |
Biosimilar , Monoclonal Antibody |
Truxima® |
10 mg/mL |
– |
2 mg |
tba |
tba |
234,00 € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
05/2018 |
126,90 € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
09/2018 |
126,90 € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
12/2018 |
126,90 € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
02/2019 |
126,90 € |
Evidentic GmbH
Martin-Buber-Str. 10
14163 Berlin